logo-loader
Rhinomed Ltd

Rhinomed registers Pronto vapour release technology as a class-one medical device with both US and Australian regulators

The new Pronto range of dual action products is set to go on sale in the second half of this year.

1558070766_Rhinomed-head.jpg
When the Pronto device is stored in its case in the recharge position, the device is replenished with essential oil formulation ready for reuse

Rhinomed Ltd (ASX:RNO) has registered its revolutionary new Pronto rechargeable vapour release technology with both the US Food and Drug Administration (FDA) and the Australian Therapeutic Goods Administration (TGA) as a class-one medical device.

In the US, Rhinomed has now completed registration of Pronto covering both variants – Pronto Sleep and Pronto Clear – as a class-one medical device with the FDA.

The company also confirmed registration of Pronto as a class-one medical device with the TGA in Australia, using Rhinomed’s existing TGA listing under the same product category as its Mute and Turbine products.

Shares increased up to 16% to 25 cents.

READ: Rhinomed to launch vapour release technology after securing US purchase orders

The new Pronto OTC range includes the novel Airstream release systems, which allows the continuous release of an essential oil blend into the nasal airstream over a set period.

By combining this new vapour release technology with the Mute’s stenting action, Rhinomed provides users with a unique dual action device that not only improves nasal airflow but delivers a soothing blend of essential oils to help clear a stuffy nose.

Pronto also includes a novel recharging and storage case that allows Pronto to be recharged before each use.

 

 

The company is completing production and will be shipping the new products at the end of May and confirms that both products will be sold online through select retail partners.

Quick facts: Rhinomed Ltd

Price: $0.24

Market: ASX
Market Cap: $33.35 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Musgrave Minerals signs $18 million earn-in JV with...

Musgrave Minerals Ltd (ASX:MGV) managing director Robert Waugh updates Proactive on the signing of an $18 million earn-in joint venture agreement with Evolution Mining centred on the Lake Area of the Cue Project in W.A.  Evolution can earn 75% in the area by sole funding $18 million in...

13 hours, 5 minutes ago

2 min read